Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells

Jian Min, Valeria Sanabria Guillen, Abhishek Sharma, Yuechao Zhao, Yvonne Ziegler, Ping Gong, Christopher G. Mayne, Sathish Srinivasan, Sung Hoon Kim, Kathryn E. Carlson, Kendall W. Nettles, Benita S Katzenellenbogen, John A. Katzenellenbogen

Research output: Contribution to journalArticle

Abstract

To search for new antiestrogens more effective in treating breast cancers, we explored alternatives to the acrylic acid side chain used in many antiestrogens. To facilitate our search, we used a simple adamantyl ligand core that by avoiding stereochemical issues enabled rapid synthesis of acrylate ketone, ester, and amide analogs. All compounds were high affinity estrogen receptor α (ERα) ligands but displayed a range of efficacies and potencies as antiproliferative and ERα-downregulating agents. There were large differences in activity between compounds having minor structural changes, but antiproliferative and ERα-downregulating efficacies generally paralleled one another. Some compounds with side chain polar groups had particularly high affinities. The secondary carboxamides had the best cellular activities, and the 3-hydroxypropylamide was as efficacious as fulvestrant in suppressing cell proliferation and gene expression. This study has produced structurally novel antiestrogens based on a simple adamantyl core structure with acrylate side chains optimized for cellular antagonist activity.

Original languageEnglish (US)
Pages (from-to)6321-6336
Number of pages16
JournalJournal of Medicinal Chemistry
Volume60
Issue number14
DOIs
StatePublished - Jul 27 2017

Fingerprint

Estrogen Receptor Modulators
Estrogen Receptors
Breast Neoplasms
Down-Regulation
Ligands
Ketones
Amides
Esters
Cell Proliferation
Gene Expression
acrylic acid

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells. / Min, Jian; Guillen, Valeria Sanabria; Sharma, Abhishek; Zhao, Yuechao; Ziegler, Yvonne; Gong, Ping; Mayne, Christopher G.; Srinivasan, Sathish; Kim, Sung Hoon; Carlson, Kathryn E.; Nettles, Kendall W.; Katzenellenbogen, Benita S; Katzenellenbogen, John A.

In: Journal of Medicinal Chemistry, Vol. 60, No. 14, 27.07.2017, p. 6321-6336.

Research output: Contribution to journalArticle

Min, J, Guillen, VS, Sharma, A, Zhao, Y, Ziegler, Y, Gong, P, Mayne, CG, Srinivasan, S, Kim, SH, Carlson, KE, Nettles, KW, Katzenellenbogen, BS & Katzenellenbogen, JA 2017, 'Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells', Journal of Medicinal Chemistry, vol. 60, no. 14, pp. 6321-6336. https://doi.org/10.1021/acs.jmedchem.7b00585
Min, Jian ; Guillen, Valeria Sanabria ; Sharma, Abhishek ; Zhao, Yuechao ; Ziegler, Yvonne ; Gong, Ping ; Mayne, Christopher G. ; Srinivasan, Sathish ; Kim, Sung Hoon ; Carlson, Kathryn E. ; Nettles, Kendall W. ; Katzenellenbogen, Benita S ; Katzenellenbogen, John A. / Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 14. pp. 6321-6336.
@article{8a914c3bcbce4a26a206ceb0c2f8cab8,
title = "Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells",
abstract = "To search for new antiestrogens more effective in treating breast cancers, we explored alternatives to the acrylic acid side chain used in many antiestrogens. To facilitate our search, we used a simple adamantyl ligand core that by avoiding stereochemical issues enabled rapid synthesis of acrylate ketone, ester, and amide analogs. All compounds were high affinity estrogen receptor α (ERα) ligands but displayed a range of efficacies and potencies as antiproliferative and ERα-downregulating agents. There were large differences in activity between compounds having minor structural changes, but antiproliferative and ERα-downregulating efficacies generally paralleled one another. Some compounds with side chain polar groups had particularly high affinities. The secondary carboxamides had the best cellular activities, and the 3-hydroxypropylamide was as efficacious as fulvestrant in suppressing cell proliferation and gene expression. This study has produced structurally novel antiestrogens based on a simple adamantyl core structure with acrylate side chains optimized for cellular antagonist activity.",
author = "Jian Min and Guillen, {Valeria Sanabria} and Abhishek Sharma and Yuechao Zhao and Yvonne Ziegler and Ping Gong and Mayne, {Christopher G.} and Sathish Srinivasan and Kim, {Sung Hoon} and Carlson, {Kathryn E.} and Nettles, {Kendall W.} and Katzenellenbogen, {Benita S} and Katzenellenbogen, {John A.}",
year = "2017",
month = "7",
day = "27",
doi = "10.1021/acs.jmedchem.7b00585",
language = "English (US)",
volume = "60",
pages = "6321--6336",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "14",

}

TY - JOUR

T1 - Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells

AU - Min, Jian

AU - Guillen, Valeria Sanabria

AU - Sharma, Abhishek

AU - Zhao, Yuechao

AU - Ziegler, Yvonne

AU - Gong, Ping

AU - Mayne, Christopher G.

AU - Srinivasan, Sathish

AU - Kim, Sung Hoon

AU - Carlson, Kathryn E.

AU - Nettles, Kendall W.

AU - Katzenellenbogen, Benita S

AU - Katzenellenbogen, John A.

PY - 2017/7/27

Y1 - 2017/7/27

N2 - To search for new antiestrogens more effective in treating breast cancers, we explored alternatives to the acrylic acid side chain used in many antiestrogens. To facilitate our search, we used a simple adamantyl ligand core that by avoiding stereochemical issues enabled rapid synthesis of acrylate ketone, ester, and amide analogs. All compounds were high affinity estrogen receptor α (ERα) ligands but displayed a range of efficacies and potencies as antiproliferative and ERα-downregulating agents. There were large differences in activity between compounds having minor structural changes, but antiproliferative and ERα-downregulating efficacies generally paralleled one another. Some compounds with side chain polar groups had particularly high affinities. The secondary carboxamides had the best cellular activities, and the 3-hydroxypropylamide was as efficacious as fulvestrant in suppressing cell proliferation and gene expression. This study has produced structurally novel antiestrogens based on a simple adamantyl core structure with acrylate side chains optimized for cellular antagonist activity.

AB - To search for new antiestrogens more effective in treating breast cancers, we explored alternatives to the acrylic acid side chain used in many antiestrogens. To facilitate our search, we used a simple adamantyl ligand core that by avoiding stereochemical issues enabled rapid synthesis of acrylate ketone, ester, and amide analogs. All compounds were high affinity estrogen receptor α (ERα) ligands but displayed a range of efficacies and potencies as antiproliferative and ERα-downregulating agents. There were large differences in activity between compounds having minor structural changes, but antiproliferative and ERα-downregulating efficacies generally paralleled one another. Some compounds with side chain polar groups had particularly high affinities. The secondary carboxamides had the best cellular activities, and the 3-hydroxypropylamide was as efficacious as fulvestrant in suppressing cell proliferation and gene expression. This study has produced structurally novel antiestrogens based on a simple adamantyl core structure with acrylate side chains optimized for cellular antagonist activity.

UR - http://www.scopus.com/inward/record.url?scp=85026362122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026362122&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b00585

DO - 10.1021/acs.jmedchem.7b00585

M3 - Article

VL - 60

SP - 6321

EP - 6336

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 14

ER -